194 patents
Page 5 of 10
Utility
Anti-idiotype Antibodies Targeting Anti-bcma Chimeric Antigen Receptor
3 Mar 22
High affinity antibodies capable of binding to a single-chain variable fragment (scFv) of anti-BCMA antibody, for example, the scFv expressed on cell surface as a portion of a chimeric antigen receptor (CAR).
Henia DAR, Lalit KUMAR
Filed: 23 Aug 21
Utility
Universal Donor Cells
3 Mar 22
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating the genetically modified cells are provided herein.
Alireza Rezania, Rebeca Ramos-Zayas
Filed: 19 Nov 21
Utility
Gene-editing Compositions and Methods to Modulate Faah for Treatment of Neurological Disorders
24 Feb 22
The disclosure provides systems (e.g., CRISPR/Cas systems) for introducing an edit in a genomic DNA molecule comprising the fatty acid amide hydrolase gene (FAAH) and/or the FAAH pseudogene (FAAH-OUT).
Seshidhar Reddy Police, Tony Ho, Yanfei Yang, Hemangi Chaudhari, Anandan Paldurai
Filed: 20 Aug 21
Utility
Methods and compositions for treating cancer
22 Feb 22
Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Mary-Lee Dequéant, Zinkal Samir Padalia
Filed: 23 Apr 21
Utility
Materials and Methods for Treatment of Usher Syndrome Type 2A And/or Non-syndromic Autosomal Recessive Retinitis Pigmentosa (Arrp)
17 Feb 22
The present application provides materials and methods for treating a patient with one or more of Usher Syndrome Type 2A and ARRP, both ex vivo and in vivo; materials and methods for editing an USH2A gene containing a guanine deletion at nucleotide position c.2299.
Mariacarmela Allocca, Akiko Noma, Abraham Scaria
Filed: 2 Aug 21
Utility
Materials and Methods for Treatment of Spinocerebellar Ataxia Type 1 (SCA1) and Other Spinocerebellar Ataxia Type 1 Protein (ATXN1) Gene Related Conditions or Disorders
17 Feb 22
The present disclosure provides materials and methods for treating a patient with one or more conditions or disorders associated with ATXN1 whether ex vivo or in vivo.
Ante Sven LUNDBERG, Samarth KULKARNI, Lawrence KLEIN, Hari Kumar PADMANABHAN
Filed: 20 Feb 18
Utility
OPTIMIZED mRNA ENCODING CAS9 FOR USE IN LNPs
17 Feb 22
The present disclosure relates generally to novel lipid nanoparticle (LNP)-based compositions useful for, e.g., the delivery of a site-specific endonuclease or a nucleic acid molecule encoding same, into a target cell.
Christopher J. CHENG, Andrew SCHARENBERG, Kui WANG, Shailendra SANE
Filed: 26 Nov 19
Utility
Anti-idiotype Antibodies Targeting ANTI-CD70 Chimeric Antigen Receptor
10 Feb 22
High affinity antibodies capable of binding to a single-chain variable fragment (scFv) of anti-CD70 antibody, for example, the scFv expressed on cell surface as a portion of a chimeric antigen receptor (CAR).
Lalit KUMAR, Mary-Lee DEQUEANT
Filed: 3 Aug 21
Utility
Allogeneic Cell Therapy of Acute Lymphoblastic Leukemia Using Genetically Engineered T Cells Targeting CD19
27 Jan 22
Methods for treating a B cell malignancy comprising a population of genetically engineered immune cells (e.g., T cells), which express a chimeric antigen receptor (CAR) specific to CD19 and optionally an NK cell inhibitor (e.g., daratumumab).
Jonathan Alexander TERRETT, Demetrios KALAITZIDIS, Ewelina MORAWA, Mark BENTON
Filed: 25 Jun 21
Utility
Genetically Engineered T Cells with REGNASE-1 And/or Tgfbrii Disruption Have Improved Functionality and Persistence
20 Jan 22
A population of genetically engineered T cells, comprising a disrupted Reg1 gene and/or a disrupted TGFBRII gene.
Mary-Lee Dequeant, Demetrios Kalaitzidis, Mohammed Ghonime
Filed: 4 Oct 21
Utility
Universal Donor Cells
20 Jan 22
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza REZANIA, Rebeca RAMOS-ZAYAS
Filed: 23 Jul 21
Utility
Materials and Methods for Treatment of Hereditary Haemochromatosis
13 Jan 22
Materials and methods for treating a patient with hereditary hemochromatosis (HHC), both ex vivo and in vivo, and materials and methods for modulating the expression, function, or activity of a haemochromatosis (HFE) gene in a cell by genome editing.
Roman Lvovitch Bogorad, Chad Albert Cowan, Ante Sven Lundberg
Filed: 9 Jul 21
Utility
Use of Chimeric Antigen Receptor T Cells and NK Cell Inhibitors for Treating Cancer
13 Jan 22
Methods for improving a clinical outcome in a subject comprising administering to a subject in need of the treatment a population of genetically engineered immune cells (e.g., T cells), which express a chimeric antigen receptor (CAR) and a natural killer (NK) cell inhibitor (e.g., daratumumab).
Jonathan Alexander Terrett, Lawrence Klein, Ewelina Morawa
Filed: 28 Sep 21
Utility
Compositions and Methods for Nhej-mediated Genome Editing
6 Jan 22
The present application relates to compositions and methods for genome editing in cells by homology-independent mechanisms, in particular for genome editing in cells that lack the machinery necessary for repair by homology-dependent mechanisms.
Gregory J. Cost, Gene l. Uenishi
Filed: 30 Oct 19
Utility
Materials and Methods for Treatment of Usher Syndrome Type 2A
30 Dec 21
The present application provides materials and methods for treating a patient with Usher Syndrome Type 2A, both ex vivo and in vivo; materials and methods for editing a USH2A gene in a human cell; materials and methods for editing an USH2A gene containing an IVS40 mutation; materials and methods for treating a patient with an USH2A gene containing an IVS40 mutation; and a method for deleting a sequence comprising an IVS40 mutation within a USH2A gene of a cell.
Albena KANTARDZHIEVA, Akiko NOMA, Abraham SCARIA
Filed: 28 Jun 21
Utility
Materials and methods for engineering cells and uses thereof in immuno-oncology
28 Dec 21
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 12 Apr 21
Utility
Materials and methods for engineering cells and uses thereof in immuno-oncology
21 Dec 21
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 12 Apr 21
Utility
ANTI-CD70 Antibodies and Uses Thereof
9 Dec 21
High affinity and specificity antibodies capable of binding to human CD70.
Jason Sagert, Minh Thu PHAM
Filed: 3 Jun 21
Utility
Materials and methods for engineering cells and uses thereof in immuno-oncology
7 Dec 21
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 29 Sep 20
Utility
Genetically Engineered Car T Cells That Secret INTERLEUKIN-12 and Therapeutic Uses Thereof
25 Nov 21
Genetically engineered immune cells such as T cells capable of secreting an interleukin-12 protein, for example, upon activation of the T cells.
Mohammed Ghonime, Demetrios Kalaitzidis, Jason Sagert, Jonathan Alexander Terrett
Filed: 21 May 21